Prevention of prion disease symptoms in mice with deep PrP lowering

J. E. Gentile; J. E. Farley; M. N. Kelemen; M. A. Mortberg; T. L. Corridon; V. Laversenne; J. R. Bombardier; C. Umana; K. DeSouza-Lenz; M. Howard; K. Guzman; N. Chan; D. A. Sprague; A. A. Coffey; J. Trapilo; S. Mallat; R. Tymon; O. Adeduji; D. Cha; M. K. Schlegel; A. Castoreno; L. Woods; T. M. Nguyen; M. Gao; A. Avbersek; O. A. Harari; C. A. Kyratsous; K. M. Brown; K. Fitzgerald; H. Peng; S. M. Vallabh; E. V. Minikel

doi:10.64898/2026.10.22.761034

AI summary · DOI: 10.64898/2026.10.22.761034 · bioRxiv: Neuroscience

Prevention of prion disease symptoms in mice with deep PrP lowering

J. E. Gentile, J. E. Farley, M. N. Kelemen, M. A. Mortberg, T. L. Corridon, V. Laversenne, J. R. Bombardier, C. Umana,

and 24 more authors

K. DeSouza-Lenz, M. Howard, K. Guzman, N. Chan, D. A. Sprague, A. A. Coffey, J. Trapilo, S. Mallat, R. Tymon, O. Adeduji, D. Cha, M. K. Schlegel, A. Castoreno, L. Woods, T. M. Nguyen, M. Gao, A. Avbersek, O. A. Harari, C. A. Kyratsous, K. M. Brown, K. Fitzgerald, H. Peng, S. M. Vallabh, E. V. Minikel

Original paper Published on 24 Oct. 2026 bioRxiv preprint License: CC BY 4.0 Also in: fr

How to read this summary? Illustrated guide

The essentials

Deep PrP lowering with a C16-conjugated siRNA prevented symptoms through 500 days in prion-infected mice treated early and extended survival when treatment began after symptoms.

Question

Can therapeutic PrP lowering prevent prion disease symptoms rather than merely slow progression? The study also examines treatment after symptom onset and whether deep lowering addresses strains with differing responses to modest lowering.

Method

The authors delivered a potent C16-conjugated siRNA into mouse cerebrospinal fluid, reducing PrP to 12% residual in whole brain hemispheres, and evaluated early chronic and symptomatic treatment. They assessed prion replication, neuropathological changes, and responses of RML and Fukuoka-1 strains, and tested human PRNP-targeting siRNA in humanized mice and cynomolgus macaques.

Findings

Result CSF-delivered C16-conjugated siRNA reduced PrP to 12% residual in whole brain hemispheres of mice.
See the passage in the paper
A highly potent PrP-lowering C16-conjugated siRNA delivered into the cerebrospinal fluid (CSF) of mice lowers PrP to 12% residual in whole brain hemispheres.
Result Early chronic treatment kept infected mice symptom-free through 500 days post-inoculation, suppressed prion replication 100-fold, and minimized neuropathological changes.
See the passage in the paper
Early chronic treatment keeps prion-infected animals free from symptoms through 500 days post-inoculation, suppressing prion replication by 100-fold and minimizing neuropathological changes.
Result Treatment of symptomatic mice increased survival and reduced prion seeding activity 10-fold.
See the passage in the paper
Treatment of symptomatic mice profoundly increases survival and attenuates prion seeding activity 10-fold.
Authors’ interpretation The authors suggest that RML and Fukuoka-1 may differ in neurotoxicity rather than replication kinetics, with both responding effectively to deep PrP lowering.
See the passage in the paper
Prion strains that are relatively responsive (RML) and recalcitrant (Fukuoka-1) to modest (~50%) PrP lowering exhibit indistinguishable kinetics of prion replication, and may instead differ in their neurotoxicity; both are effectively addressed by deep knockdown.
Result Human PRNP-targeting siRNA durably lowered PrP in humanized mice and in the brain and CSF of cynomolgus macaques.
See the passage in the paper
siRNA targeting human PRNP durably lowers PrP in humanized mice, and in brain and CSF of cynomolgus macaques.

Limitations

The reported therapeutic evidence is from animal models and does not establish clinical efficacy in humans.
Symptom prevention is reported through 500 days post-inoculation, not as lifelong prevention.
See the passage in the paper
Early chronic treatment keeps prion-infected animals free from symptoms through 500 days post-inoculation, suppressing prion replication by 100-fold and minimizing neuropathological changes.

Why it matters

The authors nominate PrP-lowering siRNA as a therapeutic modality for prion disease and argue that extremely deep PrP lowering is important for preventing symptoms and addressing strains less responsive to modest lowering.

Written by AI from the paper. Passages are checked word for word against the text we analysed; the rest may contain errors.

AI-generated keywords: Prion disease PrP lowering siRNA Neuroprotection Preclinical research

Read further

Comprehensive Summary
Layman's Summary
Blog article
Original abstract

This study investigates whether substantial reduction of the normal prion protein, PrP, can prevent symptoms of prion disease rather than merely slow its progression. Because PrP is the host protein required for prion propagation, lowering its levels is a potential therapeutic strategy. Previous animal studies showed that PrP reduction could slow disease, but, according to the authors, no therapeutic intervention had previously demonstrated prevention of symptoms. The researchers also examined whether substantial PrP reduction could benefit animals already showing symptoms and overcome strain-specific differences in treatment responsiveness. The investigators used a highly potent small interfering RNA (siRNA) designed to lower PrP. The siRNA was conjugated to C16 and delivered into the cerebrospinal fluid, which surrounds the brain and spinal cord. In mice, this approach reduced PrP levels measured in whole-brain hemispheres to 12% of baseline—an approximately 88% reduction. The study evaluated early, ongoing treatment in prion-infected animals as well as treatment initiated after symptoms appeared. It also compared the RML and Fukuoka-1 prion strains, which differ in their responsiveness to more modest PrP reductions. To explore relevance beyond conventional mouse models, the researchers tested siRNA targeting human PRNP in humanized mice and examined PrP lowering in cynomolgus macaques. The strongest reported finding was that early, ongoing treatment kept prion-infected mice symptom-free through 500 days after inoculation. This protection was accompanied by a 100-fold suppression of prion replication and minimal neuropathological changes. These findings suggest that substantial PrP reduction restrained the underlying disease process during the observation period rather than simply masking symptoms. However, remaining symptom-free through 500 days does not establish lifelong prevention or complete elimination of infection. Treatment also benefited mice that were already symptomatic. The abstract reports a substantial increase in survival and a 10-fold reduction in prion seeding activity, a measure of prion material’s ability to initiate further protein misfolding. However, it does not specify the magnitude of the survival extension, the treatment schedule, or the disease stage at treatment initiation. These omissions limit assessment of how broadly the findings might apply. The strain comparison yielded another important result. RML is relatively responsive to modest PrP reductions of approximately 50%, whereas Fukuoka-1 is comparatively resistant. Nevertheless, the authors report indistinguishable prion replication kinetics for the two strains and suggest that differences in neurotoxicity may explain their differing treatment responses. Substantial PrP reduction was effective against both strains. Separately, siRNA targeting human PRNP produced durable PrP lowering in humanized mice and in the brain and cerebrospinal fluid of cynomolgus macaques. These findings support further investigation of the approach, although the macaque results demonstrate target reduction rather than protection against prion disease. Overall, the study supports substantial PrP lowering as a promising strategy for preventing symptomatic disease when treatment begins early and extending survival after symptoms emerge. Its central implication is that the extent of target reduction may be crucial to efficacy. Important limitations remain: the study is a bioRxiv preprint, and only its abstract was supplied, preventing evaluation of sample sizes, statistical analyses, dosing details, safety findings, and experimental controls. The results are preclinical; human efficacy, long-term safety, and practical treatment requirements remain unresolved.

Deep PrP Lowering Keeps Prion-Infected Mice Symptom-Free in Preclinical Study

Could lowering a single protein stop prion disease symptoms from developing, rather than simply delay their progression? A new preclinical study offers encouraging evidence. In prion-infected mice, early and ongoing treatment that sharply reduced the normal prion protein, PrP, kept animals symptom-free through 500 days after infection.

The paper, “Prevention of prion disease symptoms in mice with deep PrP lowering,” by J. E. Gentile, J. E. Farley, M. N. Kelemen, M. A. Mortberg, T. L. Corridon, V. Laversenne et al., also reports benefits when treatment began after symptoms appeared. Its central message is that how much PrP is lowered may be critical to treatment success.

These are promising animal findings, not evidence of an effective human treatment. The study is a bioRxiv preprint, and only its abstract was available for this article, limiting how thoroughly its methods and conclusions can be assessed.

Why Target the Normal Prion Protein?

Prion disease depends on the host’s normal PrP protein. Disease-associated prions drive protein misfolding, and normal PrP provides the material needed for continued propagation. Reducing that supply is therefore a potential way to restrain the disease process.

Previous animal studies showed that lowering PrP could slow disease. According to the researchers, however, no therapeutic intervention had previously demonstrated prevention of symptoms. This study asked whether a much deeper reduction could cross that threshold—and whether it could also help animals already showing symptoms.

A Stronger Reduction, Delivered to the Central Nervous System

The investigators used a highly potent small interfering RNA, or siRNA, designed to lower PrP production. The siRNA was conjugated to C16 and delivered into the cerebrospinal fluid, which surrounds the brain and spinal cord.

In mice, treatment reduced PrP measured in whole-brain hemispheres to 12% of baseline—approximately an 88% reduction. That is substantially deeper than the roughly 50% reductions discussed in the study’s comparison of treatment responsiveness across prion strains.

The distinction matters: evidence that modest lowering slows disease does not necessarily predict what happens when far less PrP remains available.

What the Mouse Experiments Found

Early treatment prevented symptoms during the observation period

The strongest result came from prion-infected mice receiving early, ongoing treatment. They remained symptom-free through 500 days after inoculation. This protection was accompanied by a 100-fold suppression of prion replication and minimal neuropathological changes.

Together, these findings suggest that treatment restrained the underlying disease process rather than merely hiding outward symptoms. But the observation window is important. Remaining symptom-free through 500 days does not prove lifelong prevention, complete clearance of infection, or protection after treatment stops.

Treatment also helped after symptoms appeared

In symptomatic mice, the abstract reports a substantial survival increase and a 10-fold reduction in prion seeding activity. Seeding activity measures prion material’s ability to initiate further protein misfolding; reducing it suggests an effect on disease-related biological activity.

However, the abstract does not specify how much longer the animals survived, the treatment schedule, or the precise disease stage when treatment began. Without those details, it is difficult to judge how broadly the benefit might apply or how late treatment could remain useful.

Deep Lowering Worked Across Two Different Strains

The researchers compared the RML and Fukuoka-1 prion strains. RML is relatively responsive to modest PrP reductions of about 50%, while Fukuoka-1 is comparatively resistant. Substantial PrP lowering was effective against both.

The authors also report indistinguishable prion replication kinetics for the two strains. They suggest that differences in neurotoxicity—how the strains damage nervous tissue—may help explain their different responses to more modest lowering. This remains an interpretation, but the results support testing whether deeper target reduction can overcome some strain-specific treatment barriers.

Steps Toward Human Relevance

The study also examined siRNA targeting human PRNP, the gene encoding PrP. It produced durable PrP lowering in humanized mice and in the brain and cerebrospinal fluid of cynomolgus macaques.

These experiments strengthen the rationale for further development beyond conventional mouse models. Crucially, though, the macaque findings demonstrate target reduction, not protection against prion disease. Successfully lowering a protein and showing clinical benefit are separate milestones.

What Still Needs to Be Established?

The findings leave several important questions unresolved:

Whether similarly deep PrP lowering would prevent symptoms or extend survival in humans.
Whether substantial, sustained reduction is safe over long periods.
What doses and treatment intervals would be needed in practice.
How outcomes vary with disease stage and prion strain.

Because only the abstract was supplied, sample sizes, statistical analyses, experimental controls, dosing details, and safety findings could not be evaluated.

The takeaway is promising but bounded: deep PrP lowering prevented symptoms during a defined observation period in early-treated mice and benefited symptomatic animals. It offers a strong reason for further investigation—not yet a proven route to preventing or treating human prion disease.

Created on 27 Oct. 2026

Was this synthesis useful?

Score: 0

Ask questions about this paper to our AI assistant

How to chat with this paper? Illustrated guide

You can also chat with multiple papers at once here.

AI assistant instructions?

Tools for this paper

Explain it differently 3 free rewrites left today

Save to a collection Group papers in collections to compare them, chat with them and export them. Create a free account Log in

Export BibTeX · RIS (Zotero, Mendeley, EndNote) · Markdown (Notion, Obsidian)

Advanced tools Premium

For researchers who follow a field closely: citation alerts, journal-club slides, version comparison and Zotero export. Discover Premium

Zotero

Citation alerts Citation alerts guide

Who works on it? The people and institutions who publish on its topic

Weekly letter Presented in "Brain and behaviour this week" of 26 October 2026. Brain and behaviour this week: Lowering a protein, finding a memory, catching a rhythm

Journal club Premium+ Slides to present it

Talk about it in public Premium+ Press kit: release, questions, hype check Press kit guide

Disclaimer: The AI-based summarization tool and virtual assistant provided on this website may not always provide accurate and complete summaries or responses. We encourage you to carefully review and evaluate the generated content to ensure its quality and relevance to your needs.

Prevention of prion disease symptoms in mice with deep PrP lowering

The essentials

Question

Method

Findings

Limitations

Why it matters

Read further

Definitions

Deep PrP Lowering Keeps Prion-Infected Mice Symptom-Free in Preclinical Study

Why Target the Normal Prion Protein?

A Stronger Reduction, Delivered to the Central Nervous System

What the Mouse Experiments Found

Early treatment prevented symptoms during the observation period

Treatment also helped after symptoms appeared

Deep Lowering Worked Across Two Different Strains

Steps Toward Human Relevance

What Still Needs to Be Established?

Ask questions about this paper to our AI assistant

Tools for this paper

Advanced tools Premium

Papers around this one

Closest papers

Prior work it builds on

Go further

Cite this paper (BibTeX)